Study Finds Empagliflozin Does Not Significantly Reduce Heart Failure Hospitalizations or Death After Heart Attack

📆 4/8/2024 6:56 PM
📰 NewsMedical

⏱ Reading Time:
11 sec. here
10 min. at publisher
📊 Quality Score:
News: 36%
Publisher: 71%

Health News

Empagliflozin,Heart Attack,Heart Failure

The use of the SGLT-2 inhibitor empagliflozin after a heart attack did not show a significant benefit in reducing overall heart failure hospitalizations or death from any cause, according to a study presented at the American College of Cardiology's Annual Scientific Session. However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack.

The use of the SGLT-2 inhibitor empagliflozin after a heart attack did not significantly reduce overall heart failure hospitalizations or death from any cause, according to a study presented at the American College of Cardiology's Annual Scientific Session. However, the drug may be helpful in reducing heart failure risks following a heart attack.

Results from the EMPACT-MI trial showed that people who took empagliflozin had a lower risk of certain outcomes related to heart failure, including hospitalization, without any increased risk of adverse events

Write Comment

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Entertainment Entertainment Latest News, Entertainment Entertainment Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Popular weight loss diet 'doubles risk of heart disease death', new study findsThe 16:8 diet has been used by actress Jennifer Aniston and model Heidi Klum, but researchers claim it isn't the best long-term option.
Source: Daily_Record - 🏆 9. / 89 Read more »